Albuminuria reduction: the holy grail for kidney protection.
other · Level V
Where this comes from
- Record sourced from PubMed, PMID 17882241.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Increased urinary excretion of albumin or total protein has become firmly established as a risk predictor for progression of chronic kidney disease. Observational analyses have raised a strong hypothesis that albuminuria reduction should be a clinical treatment target. Bakris et al. report further exploration of albuminuria-lowering capabilities of intensified renin-angiotensin system inhibition in a randomized clinical trial that included patients at high cardiovascular risk, most of whom appeared to have diabetic kidney disease.
Medical subject headings
- Albuminuria
- Angiotensin II Type 1 Receptor Blockers
- Angiotensin-Converting Enzyme Inhibitors
- Biphenyl Compounds
- Ramipril
- Tetrazoles